Avanos Medical, Inc.

As of September 26, 2025, Avanos Medical, Inc. is in a mildly bearish trend, with mixed technical signals across timeframes and significant underperformance compared to the S&P 500, showing a year-to-date return of -26.07% and a one-year return of -49.89%.

As of September 26, 2025, Avanos Medical, Inc. shows a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, reporting a year-to-date return of -26.07% versus the index's 12.96%.

As of August 27, 2025, Avanos Medical, Inc. shows a mildly bearish trend with mixed technical indicators, including a mildly bullish weekly MACD and a year-to-date return of -22.86% compared to the S&P 500's 12.22%.

As of February 26, 2025, Avanos Medical, Inc. is considered a risky investment due to its overvaluation, reflected in a P/E ratio of 9, an EV to EBITDA of 6.23, and a significant underperformance of -49.28% over the past year compared to the S&P 500's 17.14% return.

As of February 26, 2025, Avanos Medical, Inc. is considered overvalued and risky, with a low P/E ratio of 9, poor financial metrics, and a year-to-date return of -23.93%, significantly underperforming the S&P 500.

As of June 17, 2025, Avanos Medical, Inc. shows a mildly bearish trend, with mixed signals from indicators like the MACD, moving averages, and Bollinger Bands across various time frames.

As of March 2022, the management team of Avanos Medical, Inc. includes Chairman Gary Blackford, CEO Joseph Woody, and several independent directors: John Byrnes, William Hawkins, Heidi Kunz, Patrick O'Leary, and Maria Sainz. They oversee the company's operations and strategic direction.

Avanos Medical, Inc. is a medical technology company specializing in surgical and interventional pain management, as well as respiratory and digestive health. As of March 2025, it reported net sales of $168 million and a market cap of $564.21 million.

As of Jun 18, Avanos Medical, Inc. has a market capitalization of 564.21 million and reported net sales of 689.20 million, with a net profit loss of 380.20 million over the latest four quarters. Shareholder's funds are at 828.50 million, and total assets amount to 1,154.20 million.